The abstract is read at the publisher; the summary is JClub's.
Metformin alleviates benzalkonium chloride–induced dry eye disease in mice by reducing corneal epithelial senescence and apoptosis, with benefits partially blocked by AMPK inhibition.
- Why it matters: Dry eye disease involves stress-induced premature senescence and oxidative stress, but metformin’s therapeutic efficacy and mechanism in non-diabetic settings are unclear.
- What they did: The study used hyperosmotic stress in human corneal epithelial cells and a BAC-induced DED mouse model, assessing viability, senescence markers, ROS, and ZO-1; AMPK involvement was tested with Compound C and NRF2 inhibition (ML385) plus transcriptomic support (GSE252984).
- The result: Metformin pretreatment reduced hyperosmolarity-driven cell death, ROS, and senescence/inflammatory marker expression via AMPK/SIRT1 and NRF2 nuclear translocation, and in vivo preserved epithelial thickness while lowering apoptosis and senescence markers in DED mice.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.